The "SMN1 Gene Spinal Muscular Atrophy Type 4 Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, aimed at detecting mutations in the SMN1 gene, which are indicative of Spinal Muscular Atrophy (SMA) Type 4. SMA Type 4, also known as adult-onset SMA, is a rare genetic disorder characterized by progressive muscle weakness and atrophy, typically manifesting in adulthood. The test is crucial for individuals with a family history of SMA or those exhibiting symptoms, as it aids in confirming the diagnosis, understanding the disease progression, and making informed decisions about management and care. The test is conducted using a sample of the individual's DNA, extracted from a blood sample or cheek swab. At DNA Labs UAE, this comprehensive genetic analysis is offered at a cost of 4400 AED, providing invaluable insights into the genetic basis of SMA Type 4 and facilitating early intervention and personalized treatment strategies.
The DNAJB2 gene is closely associated with a form of spinal muscular atrophy (SMA) known as type 5. SMA type 5 is a rare genetic disorder characterized by progressive muscle weakness and atrophy, primarily affecting the motor neurons in the spinal cord. The DNAJB2 gene plays a crucial role in the maintenance and function of these neurons. Mutations in this gene can lead to the development of SMA type 5, making genetic testing for these mutations an important tool for diagnosis and family planning.
DNA Labs UAE offers a specialized genetic test for the DNAJB2 gene to help identify mutations that are associated with spinal muscular atrophy type 5. This test is crucial for individuals with a family history of SMA or those exhibiting symptoms related to motor neuron dysfunction. By analyzing the DNAJB2 gene, the test can confirm a diagnosis, allowing for early intervention and management strategies to be implemented. Additionally, it can provide essential information for families considering future pregnancies.
The cost of the DNAJB2 gene spinal muscular atrophy type 5 genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect mutations in the DNAJB2 gene accurately. Given the complexity of genetic testing and the specific expertise required to interpret the results, the cost reflects both the technological and professional resources involved in providing accurate and actionable information for patients and their families.
The ASAH1 Gene Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME) genetic test is a specialized diagnostic examination available at DNA Labs UAE, designed to identify mutations in the ASAH1 gene. These mutations are responsible for causing SMA-PME, a rare, autosomal recessive neurodegenerative disorder. The condition is characterized by progressive muscle weakness and wasting (spinal muscular atrophy) alongside myoclonic seizures (epilepsy). The test is crucial for early detection and management of the disease, offering insights into potential treatment paths and helping in family planning for those with a history of SMA-PME. The cost of the test is set at 4400 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed to ensure accurate results.
The ATP7A gene spinal muscular atrophy distal X-linked genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATP7A gene, which are linked to a rare form of spinal muscular atrophy (SMA) known as distal X-linked SMA. This condition affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy primarily in the distal muscles, which are those farthest from the center of the body, such as hands and feet. It is an X-linked disorder, meaning it is associated with the X chromosome, and typically affects males more severely than females.
DNA Labs UAE offers this comprehensive genetic test for individuals who may be at risk of carrying or expressing the mutation associated with this form of SMA. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the ATP7A gene.
The cost of the ATP7A gene spinal muscular atrophy distal X-linked genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the genetic analysis and the specialized expertise required to interpret the results accurately. By undergoing this test, individuals and families can gain valuable insights into their genetic health, enabling them to make informed decisions about their medical care and potential treatment options.
The BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 (SMA-LED2) genetic test is a specialized diagnostic tool used to detect mutations in the BICD2 gene, which are known to cause SMA-LED2. This condition is characterized by muscle weakness and atrophy predominantly affecting the lower limbs, often leading to difficulties in walking and mobility. It is inherited in an autosomal dominant pattern, meaning that only one copy of the altered gene is sufficient to cause the disorder.
The test is conducted at DNA Labs UAE, a reputable facility known for its comprehensive genetic testing services. The process involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab to identify any mutations in the BICD2 gene.
The cost of the BICD2 Gene Spinal Muscular Atrophy Lower Extremity Autosomal Dominant Type 2 genetic test is 4400 AED. While the price may seem steep, it's important to consider the value of the information it provides, which can be crucial for early diagnosis, management, and treatment planning for affected individuals and their families. Early detection through this genetic test can significantly improve the quality of life for those with SMA-LED2 by allowing for timely interventions and support.
The DYNC1H1 gene plays a crucial role in the development and function of the nervous system, and mutations in this gene can lead to various neurological conditions, including Spinal Muscular Atrophy Lower Extremity-Predominant Type 1 (SMA-LED1), an autosomal dominant disorder. This particular form of spinal muscular atrophy is characterized by muscle weakness and atrophy primarily affecting the lower limbs. Unlike other forms of SMA, SMA-LED1 shows a pattern of inheritance where only one copy of the mutated gene from either parent is sufficient to cause the disorder.
To diagnose this condition, a genetic test is available at DNA Labs UAE, which specifically looks for mutations in the DYNC1H1 gene associated with SMA-LED1. The test is a crucial tool for confirming the diagnosis, understanding the risk of passing the condition to offspring, and guiding management and treatment decisions. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the DYNC1H1 gene. Conducting this test at DNA Labs UAE ensures access to state-of-the-art genetic testing services, provided by a team of professionals specialized in genetic disorders.
The ATXN1 gene is associated with Spinocerebellar Ataxia Type 1 (SCA1), a progressive, neurodegenerative disorder characterized by a loss of coordination and balance. This condition is inherited in an autosomal dominant pattern, meaning only one copy of the altered gene in each cell is sufficient to cause the disorder. The ATXN1 gene test is a genetic test designed to detect mutations in the ATXN1 gene, confirming the diagnosis of SCA1 and facilitating genetic counseling for affected families.
DNA Labs UAE offers the ATXN1 gene test for individuals suspected of having Spinocerebellar Ataxia Type 1 or for those with a family history of the disorder. The test is crucial for early diagnosis, management, and understanding the risk of transmission to future generations. The cost of the ATXN1 gene test at DNA Labs UAE is 4400 AED. Conducted in a state-of-the-art laboratory setting, this genetic test provides a reliable diagnosis, guiding treatment plans and support for affected individuals and their families.
The ATP2B3 Gene Spinocerebellar Ataxia Type 1 X-Linked Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the ATP2B3 gene, which are linked to the development of Spinocerebellar Ataxia Type 1 (SCA1), a condition affecting the cerebellum and leading to progressive coordination problems. This particular form of ataxia is inherited in an X-linked pattern, meaning the gene responsible for the condition is located on the X chromosome.
SCA1 is characterized by a range of symptoms, including difficulty with coordination and balance, speech impairments, and eye movement abnormalities. Early detection through genetic testing can be crucial for managing the condition, allowing for personalized treatment plans and genetic counseling for affected families.
The test is conducted at DNA Labs UAE, a leading facility in genetic diagnostics and research. The cost for the ATP2B3 Gene Spinocerebellar Ataxia Type 1 X-Linked Genetic Test is 4400 AED. The process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the lab for the presence of mutations in the ATP2B3 gene. Results from this test can provide invaluable information for affected individuals and their families regarding the management of the condition and the risk of transmission to future generations.
The AP4B1 gene SPG47 genetic test is a specialized diagnostic procedure aimed at detecting mutations in the AP4B1 gene, which are linked to Spastic Paraplegia 47 (SPG47). SPG47 is a rare form of hereditary spastic paraplegia, characterized by developmental delays, intellectual disability, and progressive spasticity. This condition is part of a group of genetic disorders known as AP-4-associated hereditary spastic paraplegia, which affects the nervous system's development and function.
Conducted at DNA Labs UAE, this genetic test is crucial for individuals suspected of having SPG47, offering them a definitive diagnosis. Understanding the genetic basis of the condition can help in managing symptoms, planning treatments, and providing genetic counseling for affected families. The test involves analyzing the patient's DNA, extracted from a blood sample, to identify mutations in the AP4B1 gene that are responsible for the disorder.
The cost of the AP4B1 gene SPG47 genetic test at DNA Labs UAE is 4400 AED. This investment covers the expenses related to the sophisticated techniques and expert analysis required to accurately identify the genetic variations associated with the condition. For families and individuals facing the challenges of SPG47, this test represents a critical step towards a better understanding of the condition and the potential for more personalized care and management strategies.
The AP5Z1 gene SPG48 genetic test is a specialized diagnostic tool designed to identify mutations in the AP5Z1 gene, which are linked to a rare condition known as Spastic Paraplegia 48 (SPG48). This condition is part of a group of disorders known as hereditary spastic paraplegias, which are characterized by progressive stiffness and weakness of the legs. The test is crucial for individuals displaying symptoms of SPG48 or those with a family history of the disorder, as it can confirm the diagnosis and assist in the development of a tailored management plan.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient's DNA sample, typically obtained through a blood draw, to detect any genetic abnormalities in the AP5Z1 gene. The process is comprehensive, employing advanced genetic sequencing technologies to ensure accurate and reliable results.
The cost of the AP5Z1 gene SPG48 genetic test at DNA Labs UAE is set at 4400 AED. While the price might seem significant, the value of the test lies in its ability to provide crucial insights into the patient's condition, thereby enabling informed decisions about treatment and management options. It's an investment in health that could significantly impact the quality of life for individuals affected by SPG48, offering them a clearer path towards managing their condition.
